¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Purified hepatitis B surface antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • viral hepatitis type D
    DÇü¹ÙÀÌ·¯½º°£¿°
  • approximal surface
    Á¢Ã˸é, ÀÎÁ¢¸é
  • articular surface
    °üÀý¸é
  • body surface mapping
    üǥ¸éÀüÀ§Áöµµ
  • cardiac surface map
    ½ÉÀåÇ¥¸éµµ
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • dorsal surface
    µîÂʸé, µÞ¸é, ¹èÃø¸é
  • fetal surface
    žÆ(ÂÊ)¸é
  • free surface
    ÀÚÀ¯¸é
  • internal surface
    ¼Ó¸é, ³»¸é
  • lateral surface
    °¡Âʸé, ¿ÜÃø¸é, Ãø¸é
  • occlusal surface
    ±³ÇÕ¸é, ¸Â¹°¸²¸é
  • potential surface
    ÀüÀ§¸é
  • proximate surface
    ÀÎÁ¢¸é
  • quadratic surface
    ÀÌÂ÷°î¸é
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • surface area
    üǥ¸éÀû, Ç¥¸éÀû
  • surface refrigeration anesthesia
    Ç¥¸é³Ãµ¿¸¶Ãë
  • body surface mapping
    üǥ¸éÀüÀ§µµ
  • cardiac surface map
    ½ÉÀåÇ¥¸éµµ
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • root surface cavity
    À̻Ѹ®¸é°ø°£
  • surface caries
    Ç¥¸é¿ì½Ä
  • surface catalysis
    Ç¥¸éÃ˸ÅÀÛ¿ë
  • surface characteristic
    Ç¥¸éƯ¼º
  • surface chemistry
    °è¸éÈ­ÇÐ
  • surface coil
    Ç¥¸éÄÚÀÏ, Ç¥¸é°ËÃâ±â
  • surface cooling
    Ç¥¸é³Ã°¢
  • surface coupling
    Ç¥¸é°áÇÕ
  • depth resolved surface coil spectroscopy
    ±íÀÌÇØ°áÇ¥¸éÄÚÀϺб¤¹ý
  • dorsal surface
    µîÂʸé, µÚ¸é
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • popliteal surface
    ¿À±Ý¸é
  • posterior articular surface
    µÚ°üÀý¸é
  • posterior articular surface for talus
    µÚ¸ñ¸»°üÀý¸é
  • posterior calcaneal articular surface
    µÚ¹ß±Á°üÀý¸é, ÈÄÁ¾°ñ°üÀý¸é(ý­ñ¢Íé Î¼ï½Øü).
  • posterior calcaneal articular surface
    µÚ¹ß²ÞÄ¡°üÀý¸é
  • posterior calcaneal articular surface
    µÚ¹ß´ÎÄáÝ¡e, ÈÄÁ¾°ñ°üÀý¸é(ý­ñ¢Íé Î¼ï½Øü). ?ÇØºÎ
  • posterior surface
    °üÀý¸é
  • posterior surface
    µÚ¸é
  • posterior surface of eyelids
    ´«²¨Ç®µÚ¸é
  • posterior surface of petrous portion
    ¹ÙÀ§µÚ¸é
  • posterior surface ³ª facies p.
    µÚ¸é, Èĸé(ý­Øü).
  • posterior surface ³ª facies p.
    µÚ¸é, Èĸé(ý­Øü).
  • pulmonary surface
    Æó¸é(øËØü).
  • pulmonary surface
    ÇãÆÄ¸é
  • pulmonary surface
    Æó¸é(øËØü).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • hepatitis A virus(HAV)
    AÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis A virus (HAV)
    AÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis B virus(HBV)
    BÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis C virus(HCV)
    CÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis D coinfection
    D Çü °£¿°µ¿½Ã°¨¿°
  • hepatitis D virus(HDV)
    DÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis E virus(HEV)
    EÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis F virus(HFV)
    FÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis G virus(HGV)
    GÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis a
    AÇü°£¿°(¡­ÊÜæú)
  • hepatitis a virus
    AÇü°£¿° ¹ÙÀÌ·¯½º
  • hepatitis b
    BÇü°£¿°(¡­ÊÜæú)
  • hepatitis b virus
    BÇü°£¿° ¹ÙÀÌ·¯½º
  • hepatitis contagiosa canis ³ª
    °³Àü¿°¼º°£¿°.
  • hepatitis d
    DÇü°£¿°(¡­ÊÜæú)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Gluteal surface
    º¼±â±Ù¸é
    [¿¾ ¿ë¾î] µÐ±Ù¸é
  • Buccal surface
    º¼¸é
    [¿¾ ¿ë¾î] Çù¸é
  • Mediastinal surface
    ¼¼·ÎÄ­¸é
    [¿¾ ¿ë¾î] Á¾°ÝºÎ
  • Internal surface
    ¼Ó¸é
    [¿¾ ¿ë¾î] ³»¸é
  • Dorsal surface of fingers
    ¼Õ°¡¶ôµî
    [¿¾ ¿ë¾î] ¼öÁö¹è¸é
  • Palmar surface of fingers
    ¼Õ°¡¶ô¹Ù´Ú
    [¿¾ ¿ë¾î] ¼öÁöÀå¸é
  • Carpal articular surface
    ¼Õ¸ñ°üÀý¸é
    [¿¾ ¿ë¾î] ¼ö±Ù°üÀý¸é
  • Inferolateral surface
    ¾Æ·¡°¡Âʸé
    [¿¾ ¿ë¾î] ÇÏ¿ÜÃø¸é
  • Inferior articular surface
    ¾Æ·¡°üÀý¸é
    [¿¾ ¿ë¾î] ÇϰüÀý¸é
  • Inferior surface
    ¾Æ·¡¸é
    [¿¾ ¿ë¾î] Çϸé
  • Vestibular surface
    ¾È¶ã¸é
    [¿¾ ¿ë¾î] ÀüÁ¤¸é
  • Medial surface
    ¾ÈÂʸé
    [¿¾ ¿ë¾î] ³»Ãø¸é
  • Medial surface
    ¾ÈÂʸé
    [¿¾ ¿ë¾î] ³»Ãø¿¬
  • Mesial surface
    ¾ÈÂʸé
    [¿¾ ¿ë¾î] ±Ù½É¸é
  • Medial and inferior surface
    ¾ÈÂÊ¸é ¹× ¾Æ·¡¸é
    [¿¾ ¿ë¾î] ³»Ãø¸é°ú Çϸé
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • K antigen
    K Ç׿ø
  • LS antigen
    LS Ç׿ø(ù÷ê«)
  • M antigen
    M Ç׿ø(ù÷ê«)
  • MHC antigen
    MHCÇ׿ø(ù÷ê«)
  • NP antigen
    NPÇ׿ø(ù÷ê«)
  • O antigen
    O Ç׿ø(ù÷ê«)
  • P antigen
    P
  • particulate antigen
    ÀÔÀÚ Ç׿ø(Ø£í­ù÷ê«)
  • penton antigen
    ÆæÅæ Ç׿ø(ù÷ê«)
  • protective antigen
    º¸È£ Ç׿ø(ÜÁûÞù÷ê«)
  • R antigen
    R Ç׿ø(ù÷ê«)
  • S antigen
    S Ç׿ø(ù÷ê«)
  • SH-antigen
    SH-Ç׿ø(ù÷ê«)
  • soluble antigen
    °¡¿ëÇ׿ø(ʦéÁù÷ê«)
  • t antigen
    t Ç׿ø(ù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
HAA hearing aid amplifier; hemolytic anemia antigen; hepatitis-associated antigen; hospital activity ana...
SSD shaded surface display; single saturating dose; Social Security disability; source-skin distance; so...
TSTA toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen...
HBsAG hepatitis B surface virus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HBsAb Hepatitis B surface antibody
HBs Ag HB surface antigen
MSA1 Merozoite surface antigen 1
MSA2 Merzoite Surface Antigen 2
RESA Ring-Infected Erythrocyte Surface Antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • fetal antigen
    ÅÂ¾Æ Ç׿ø
    Á¾¾ç °ü·Ã Ç׿øÀÇ ÀÏÁ¾, Å»ý±â Á¶Á÷¿¡¼­´Â ÀÎÁ¤µÇÁö¸¸, Á¤»óÀûÀÎ ºÐÈ­¸¦ ¹âÀº Á¶Á÷¿¡¼­´Â ÀÎÁ¤µÇÁö ¾Ê°Å³ª ±ØÈ÷ ¹Ì·® Á¸ÀçÇϰųª ÇÑ´Ù.
  • H antigen
    H Ç׿ø
    1. ¿îµ¿¼º ¼¼±ÕÀÇ Æí¸ð Ç׿ø 2. H-¹°Áú.
  • H-2 antigen
    H-2 Ç׿ø
  • heterologous antigen
    ÀÌÁ¾ Ç׿ø
  • HL-A type antigen
    ¿¡ÀÌÄ¡¿¤¿¡ÀÌ Ç׿ø
    »ç¶÷ÀÇ ÀûÇ÷±¸ ÀÌ¿ÜÀÇ ¸ðµç ¼¼Æ÷°¡ °¡Áö°í ÀÖ´Â Ç׿ø. »ç¶÷ ¹éÇ÷±¸ Ç׿øÀ̶ó°íµµ ÇÑ´Ù. H´Â »ç¶÷
  • homologous antigen
    »óµ¿ Ç׿ø
  • human histocompatibility antigen
    ÀÎü Á¶Á÷ ÀûÇÕ Ç׿ø
  • human leukocyte antigen-B27
    ÀÎü ¹éÇ÷±¸ Ç×ü-B27
    º¸Åë °­Á÷¼º ôÃß¿° ȯÀÚ¿¡¼­ ³ªÅ¸³ª´Â À¯Àü Ç¥½ÃÀÚ.
  • lymphocyte defined antigen
    ¸²ÇÁ±¸ ±ÔÁ¤ Ç׿ø
  • N-antigen
    N Ç׿ø
  • nuclear antigen
    ÇÙ Ç׿ø
  • pancreatic oncofetal antigen
    ÃéÀåÀÇ Å¾Ƽº ¾Ï Ç׿ø
  • pollen antigen
    ²É°¡·ç Ç׿ø, È­ºÐ Ç׿ø
  • polyvalent antigen
    ´Ù°¡ Ç׿ø
  • self antigen
    ÀÚ±â Ç׿ø
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
MS-1 hepatitis A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom.
Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis.
(05 Mar 2000)
murine hepatitis A form of hepatitis in mice due to synergism between the mouse hepatitis virus and Eperythrozoon coccoides.
Synonym: murine hepatitis.
(05 Mar 2000)
halothane hepatitis Hepatocellular damage said to result from the administration of halothane anaesthesia.
(05 Mar 2000)
hepatitis <pathology> Inflammation of the liver.
(18 Nov 1997)
hepatitis A <virology> A form of viral hepatitis, known as infectious hepatitis, due to its ability to be spread through personal contact with oral secretions or stool. Virus will be shed in the stools of an infected individual 2-3 weeks prior to the onset of any symptoms. Hepatitis A may also be transmitted sexually. Symptoms are similar to those of influenza, but the skin and eyes may become yellow. Recent travel to a third world country is a risk factor. There is no specific treatment but infected individuals should avoid potentially hepatotoxic substances.
The virus is a small (27nm diameter) single stranded RNA virus with some resemblance to enteroviruses such as polio.
(27 Sep 1997)
hepatitis agents, gb Proposed members of the family flaviviridae. Gbv-b causes hepatitis in tamarins and possibly humans, and is the putative aetiological agent of a non-(a-e) hepatitis, gb hepatitis.
(12 Dec 1998)
hepatitis a immunization When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain healthcare workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
hepatitis, alcoholic An acute or chronic degenerative and inflammatory lesion of the liver in the alcoholic which is potentially progressive though sometimes reversible. It does not necessarily include steatosis, fibrosis, or cirrhosis of alcoholics, although it is frequently associated with these conditions. It is characterised by liver cell necrosis, infiltration by polymorphonuclear leukocytes and lymphocytes, and mallory bodies. The morphologic changes of chronic alcoholic hepatitis are not likely to be confused with chronic hepatitis (hepatitis, chronic).
(12 Dec 1998)
hepatitis antibodies Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis.
(12 Dec 1998)
hepatitis antigens Antigens from any of the hepatitis viruses including surface, core, and other associated antigens.
(12 Dec 1998)
hepatitis, autoimmune An unresolving, predominately periportal, hepatitis, usually with hypergammaglobulinaemia and serum autoantibodies. The existence of subgroups (types 1, 2, and 3) based on serological findings are controversial. Additionally, some patients have variant forms, where there are features associated with both autoimmune hepatitis and another type of chronic liver disease (overlap syndromes) or where there are findings incompatible with autoimmune hepatitis (outlier syndromes).
(12 Dec 1998)
hepatitis A virus <virology> An RNA virus (hepatovirus) in the family Picornaviridae, that is the causative agent of viral hepatitis type A.
The virus replicates in hepatocytes and is presumed to reach the intestine via the bile duct. Transmission occurs by the faecal-oral route.
Synonym: infectious hepatitis virus.
(20 Sep 2002)
hepatitis B <virology> A form of viral hepatitis, known as serum hepatitis, because it is commonly spread through contact with infected blood products (transfusion). May also be spread sexually or from mother to infant. Hepatitis B can cause a much more severe infection than hepatitis A and can occur as an asymptomatic carrier state, a chronic infection or as cirrhosis of the liver. Those at risk (IV drug abusers, health care workers, dialysis patients, transfusion recipients, homosexuals) should be immunised with hepatitis B vaccine.
The virus is 42nm diameter, with an outer sheath enclosing inner 27nm core particle containing the circular viral DNA. Aggregates of the envelope proteins are found in plasma and are referred to as hepatitis B surface antigen (HBsAg, previously called Australia antigen). The virus can persist for long periods (and in asymptomatic carriers), association of integrated virus with hepatocellular carcinoma is now well established.
(27 Sep 1997)
hepatitis B antibodies <immunology> Antibodies to the hepatitis b antigens, including antibodies to the surface (Australia) and core of the dane particle and those to the "e" antigens.
(12 Dec 1998)
hepatitis b, chronic An inflammatory disease of the liver caused by hepatitis b virus and lasting six months or more.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á